Analyst Price Targets — PACB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 14, 2026 10:43 am | — | Barclays | $1.00 | $1.45 | TheFly | PacBio price target lowered to $1 from $1.50 at Barclays |
| August 8, 2025 11:46 am | Eve Burstein | Bernstein | $1.70 | $1.34 | TheFly | PacBio price target raised to $1.70 from $1.50 at Bernstein |
| June 25, 2025 9:12 am | Luke Sergott | Barclays | $1.50 | $1.22 | TheFly | PacBio price target lowered to $1.50 from $2 at Barclays |
| June 3, 2024 3:33 am | Tycho Peterson | Jefferies | $4.00 | $1.79 | StreetInsider | Jefferies Starts Pacific Biosciences of California (PACB) at Buy |
| May 13, 2024 12:08 pm | Tejas Savant | Morgan Stanley | $4.00 | $1.98 | TheFly | PacBio price target lowered to $4 from $10 at Morgan Stanley |
| May 13, 2024 6:50 am | David Westenberg | Piper Sandler | $2.00 | $1.77 | TheFly | PacBio price target lowered to $2 from $6.50 at Piper Sandler |
| May 10, 2024 5:25 am | Luke Sergott | Barclays | $2.00 | $1.72 | TheFly | PacBio price target lowered to $2 from $3 at Barclays |
| April 18, 2024 4:31 am | Matthew Sykes | Goldman Sachs | $2.50 | $1.40 | StreetInsider | Goldman Sachs Downgrades Pacific Biosciences of California (PACB) to Neutral |
| April 16, 2024 3:12 pm | Kyle Mikson | Canaccord Genuity | $3.50 | $1.40 | TheFly | PacBio price target lowered to $3.50 from $10 at Canaccord |
| November 16, 2022 9:16 am | — | Canaccord Genuity | $14.00 | $10.81 | Benzinga | Canaccord Genuity Maintains Buy on Pacific Biosciences, Raises Price Target to $14 |
Latest News for PACB
MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2026 financial results on Wednesday, August 5, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
MENLO PARK, Calif. , July 15, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2026 financial results on Wednesday, August 5, 2026, at 4:30 p. m. Eastern Time (1:30 p. m.
Pacific Biosciences of California (PACB) concluded the recent trading session at $1.49, signifying a -4.49% move from its prior day's close.
PACB's growth is supported by HiFi sequencing advances and product momentum, though funding pressures weigh on instrument demand.
Pacific Biosciences of California (PACB) closed the most recent trading day at $1.66, moving 1.19% from the previous trading session.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PACB.
U.S. House Trading
No House trades found for PACB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.